RenovaLase
What is RenovaLase® ?
RenovaLase® is an innovative and unique, non-invasive 2940 nm Er:YAG laser therapy for the symptoms of vaginal atrophy. It is based on non-ablative photothermal treatment of the vaginal canal. Clinical studies show that it is an efficient, easy-to-use, quick and safe procedure, eliminating the need for long-term estrogen administration.
How does RenovaLase® work?
The RenovaLase® treatment is based on laser-induced controlled mild heating of the vaginal tissue, which stimulates angiogenesis, fibroblast activity and new collagen formation, without thermal or ablative damage. The final result is a healthier thicker tissue with greater blood supply and , along with a reduction of symptoms such as dryness, itching, irritation and dyspareunia.
Unique advantages of RenovaLase™ for patients
As a non-surgical, minimally invasive procedure with laser, RenovaLase™ also represents a safer, faster and more patient-friendly solution that avoids the undesirable complications present with other vaginal treatment method including long term side-effects from medications.
Usually two to three sessions are recommended. No special pre-op preparation or post-op precautions are necessary. Patients can immediately return to their normal everyday activities.
Satisfying clinical Results
The latest scientific results presented by Dr. Marco Gambacciani1 and Dr. Adrian Gaspar2-4 clearly show a noticeable improvement in the symptoms of vaginal atrophy. Results show favourable changes in the tropism of the vaginal mucosa, with increases in collagen and vascularization as well as in the glycogen level and the epithelial thickness. There was no ablation of the tissue or thermal damage and no adverse events. The positive effects were long lasting as results were sustained at follow-up 6 months after the treatment. With no need for long-term estrogen treatment, RenovaLase® is also appropriate for patients with estrogen-dependent cancer (such as endometrial cancer, breast cancer, etc.) or with a family background of such cancers, as shown in clinical studies by Dr. Bojanini5 and Dr. Gambacciani2 .
